Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
Stephen Johnston(Royal Marsden NHS Foundation Trust), Samuel A. Jacobs(NRG Oncology), Robert C. Stein(National Health Service), I. Shalaby(Harrington Cancer Center), Maggie C.U. Cheang(Institute of Cancer Research), Andrew Dodson(National Health Service), C. Kent Osborne(Baylor College of Medicine), Michael P. Thirlwell(McGill University Health Centre), Mairead MacKenzie(The Patients Association), Duncan Wheatley(National Health Service), David Dolling(Institute of Cancer Research), Stuart McIntosh(Queen's University Belfast), Leona Batten(Institute of Cancer Research), Peter Barry(Royal Marsden Hospital), Vera Martins(National Health Service), Louise Provencher(Mount Vernon Hospital), James P. Morden(Institute of Cancer Research), Cynthia Huang Bartlett(Pfizer (United States)), María Koehler(Pfizer (United States)), Norman Wolmark(NSABP Foundation), Sophie Perry(Institute of Cancer Research), Lisa K. Jeffs(Institute of Cancer Research), Mitch Dowsett(Institute of Cancer Research), Claire Snowdon(Institute of Cancer Research), Mothaffar F. Rimawi(Baylor College of Medicine), Katherine L. Pogue–Geile(NSABP Foundation), Thomas B. Julian(Allegheny Health Network), Chris Holcombe(National Health Service), Kate Fisher(International Drug Development Institute (Belgium)), Maggie Wilcox(University of Colorado Anschutz Medical Campus), Jean Francois Boileau(McGill University), André Robidoux(Centre Hospitalier de l’Université de Montréal), Chester Cornman(NSABP Foundation), Arjun Modi(National Health Service), Judith M. Bliss(Institute of Cancer Research), Shannon Puhalla(UPMC Hillman Cancer Center), Alistair Ring(National Health Service)
Cited by 233
Related Papers
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
|New England Journal of Medicine|2005|5.3k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k